The Role of Cardiolipin in Cardiovascular Health

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Shen, Zheni ^a   Ye, Cunqi ^a,b   McCain, Keanna ^a   Greenberg, Miriam L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CARDIOLIPIN; HIGH DENSITY LIPOPROTEIN; MITOCHONDRIAL PROTEIN; PROTEIN KINASE C; THIOCTIC ACID; UBIQUINONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

APOPTOSIS; ATAXIA; ATHEROSCLEROSIS; AUTOPHAGY; BARTH SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL (TOPIC); CONGESTIVE CARDIOMYOPATHY; DIABETIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY WITH ATAXIA SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; MITOPHAGY; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TANGIER DISEASE; CARDIOVASCULAR SYSTEM; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY;

BARTH SYNDROME; CARDIOLIPINS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; SIGNAL TRANSDUCTION;

EID: 84939639368     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/891707     Document Type: Review

References (190)

1. J. H. De Bruijn, "Chemical structure and serological activity of natural and synthetic cardiolipin and related compounds," British Journal of Venereal Diseases, vol. 42, no. 2, pp. 125-128, 1966
2. M. Schlame, S. Brody, andK. Y. Hostetler, "Mitochondrial cardiolipin in diverse eukaryotes," European Journal of Biochemistry, vol. 212, no. 3, pp. 727-733, 1993
3. A. S. Joshi, J. Zhou,V. M. Gohil, S. Chen, andM. L. Greenberg, "Cellular functions of cardiolipin in yeast," Biochimica et Biophysica Acta, vol. 1793, no. 1, pp. 212-218, 2009
4. Q. Zhong, J. Gvozdenovic-Jeremic, P. Webster, J. Zhou, and M. L. Greenberg, "Loss of function of KRE5 suppresses temperature sensitivity of mutants lacking mitochondrial anionic lipids," Molecular Biology of the Cell, vol. 16, no. 2, pp. 665-675, 2005
5. S. Chen, M. Tarsio, P. M. Kane, and M. L. Greenberg, "Cardiolipin mediates cross-talk between mitochondria and the vacuole," Molecular Biology of the Cell, vol. 19, no. 12, pp. 5047-5058, 2008
6. J. Zhou, Q. Zhong, G. Li, and M. L. Greenberg, "Loss of cardiolipin leads to longevity defects that are alleviated by alterations in stress response signaling,"TheJournal of Biological Chemistry, vol. 284, no. 27, pp. 18106-18114, 2009
7. S. Chen, D. Liu, R. L. Finley Jr., and M. L. Greenberg, "Loss of mitochondrial DNA in the yeast cardiolipin synthase crd1 mutant leads to up-regulation of the protein kinase Swe1p that regulates the G2/M transition," The Journal of Biological Chemistry, vol. 285, no. 14, pp. 10397-10407, 2010
8. X.-X. Li, B. Tsoi, Y.-F. Li, H. Kurihara, and R.-R. He, "Cardiolipin and its different properties in mitophagy and apoptosis," Journal of Histochemistry & Cytochemistry, vol. 63, no. 5, pp. 301-311, 2015
9. K. Y. Hostetler,H. vandenBosch, andL. L. M. vanDeenen, "The mechanism of cardiolipin biosynthesis in liver mitochondria," Biochimica et Biophysica Acta, vol. 260, no. 3, pp. 507-513, 1972
10. H.-F. Tian, J.-M. Feng, and J.-F. Wen, "The evolution of cardiolipin biosynthesis and maturation pathways and its implications for the evolution of eukaryotes," BMC Evolutionary Biology, vol. 12, no. 1, article 32, 2012
11. Y. Tamura, Y. Harada, S.-I. Nishikawa et al., "Tam41 is a CDPdiacylglycerol synthase required for cardiolipin biosynthesis in mitochondria," CellMetabolism, vol. 17, no. 5, pp. 709-718, 2013
12. S. Kutik, M. Rissler, X. L. Guan et al., "The translocator maintenance protein Tam41 is required for mitochondrial cardiolipin biosynthesis," Journal of Cell Biology, vol. 183, no. 7, pp. 1213-1221, 2008
13. M. R. Steiner and R. L. Lester, "In vitro studies of phospholipid biosynthesis in Saccharomyces cerevisiae," Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, vol. 260, no. 2, pp. 222-243, 1972
14. S.-C. Chang, P. N. Heacock, C. J. Clancey, and W. Dowhan, "The PEL1 gene (renamed PGS1) encodes the phosphatidylglycerophosphate synthase of Saccharomyces cerevisiae,"TheJournal of Biological Chemistry, vol. 273, no. 16, pp. 9829-9836, 1998
15. T. Hirabayashi, T. J. Larson, and W. Dowhan, "Membraneassociated phosphatidylglycerophosphate synthetase from Escherichia coli: purification by substrate affinity chromatography on cytidine 5-Diphospho-1,2-diacyl-sn-glycerol sepharose," Biochemistry, vol. 15, no. 24, pp. 5205-5211, 1976
16. H. van den Bosch, L. M. van Golde, and L. L. van Deenen, "Dynamics of phosphoglycerides," Ergebnisse der Physiologie, vol. 13, pp. 13-145, 1972
17. B. L. Kelly and M. L. Greenberg, "Characterization and regulation of phosphatidylglycerolphosphate phosphatase in Saccharomyces cerevisiae," Biochimica et Biophysica Acta-Lipids and Lipid Metabolism, vol. 1046, no. 2, pp. 144-150, 1990
18. J. Zhang, Z. Guan, A. N. Murphy et al., "Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis," Cell Metabolism, vol. 13, no. 6, pp. 690-700, 2011
19. J. Xiao, J. L. Engel, J. Zhang, M. J. Chen, G. Manning, and J. E. Dixon, "Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 29, pp. 11860-11865, 2011
20. C. Osman,M. Haag, F. T. Wieland, B. Brügger, and T. Langer, "A mitochondrial phosphatase required for cardiolipin biosynthesis: The PGP phosphatase Gep4," The EMBO Journal, vol. 29, no. 12, pp. 1976-1987, 2010
21. D. Chen, X.-Y. Zhang, and Y. Shi, "Identification and functional characterization of hCLS1, a human cardiolipin synthase localized in mitochondria," Biochemical Journal, vol. 398, no. 2, pp. 169-176, 2006
22. B. Lu, F. Y. Xu,Y. J. Jiang et al., "Cloning andcharacterizationof a cDNA encoding human cardiolipin synthase (hCLS1)," Journal of Lipid Research, vol. 47, no. 6, pp. 1140-1145, 2006
23. R. H. Houtkooper, H. Akbari, H. van Lenthe et al., "Identification and characterization of human cardiolipin synthase," FEBS Letters, vol. 580, no. 13, pp. 3059-3064, 2006
24. G. Tuller, C. Hrastnik, G. Achleitner, U. Schiefthaler, F. Klein, and G. Daum, "YDL142c encodes cardiolipin synthase (Cls1p) and is non-essential for aerobic growth of Saccharomyces cerevisiae," FEBS Letters, vol. 421, no. 1, pp. 15-18, 1998
25. F. Jiang, H. S. Rizavi, and M. L. Greenberg, "Cardiolipin is not essential for the growth of Saccharomyces cerevisiae on fermentable or non-fermentable carbon sources," Molecular Microbiology, vol. 26, no. 3, pp. 481-491, 1997
26. S.-C. Chang, P. N. Heacock, E. Mileykovskaya, D. R. Voelker, and W. Dowhan, "Isolation and characterization of the gene (CLS1) encoding cardiolipin synthase in Saccharomyces cerevisiae," Journal of Biological Chemistry, vol. 273, no. 24, pp. 14933-14941, 1998
27. H. van den Bosch, "Phosphoglyceride metabolism," Annual Review of Biochemistry, vol. 43, pp. 243-277, 1974
28. C. Ye, Z. Shen, and M. L. Greenberg, "Cardiolipin remodeling: A regulatory hub for modulating cardiolipin metabolism and function," Journal of Bioenergetics and Biomembranes, 2014
29. W. E. M. Lands, "Metabolism of glycerolipids. II. Theenzymatic acylation of lysolecithin," Journal of Biological Chemistry, vol. 235, no. 8, pp. 2233-2237, 1960
30. A. Beranek, G. Rechberger, H. Knauer, H. Wolinski, S. D. Kohlwein, and R. Leber, "Identification of a cardiolipin-specific phospholipase encoded by the gene CLD1 (YGR110W) in yeast," The Journal of Biological Chemistry, vol. 284, no. 17, pp. 11572-11578, 2009
31. A. G. Buckland, A. R. Kinkaid, and D. C. Wilton, "Cardiolipin hydrolysis by human phospholipases A2: The multiple enzymatic activities of human cytosolic phospholipase A2," Biochimica et Biophysica Acta-Lipids and Lipid Metabolism, vol. 1390, no. 1, pp. 65-72, 1998
32. Y.-H. Hsu, D. S. Dumlao, J. Cao, and E. A. Dennis, "Assessing phospholipase A2 activity toward cardiolipin by mass spectrometry," PLoS ONE, vol. 8, no. 3,Article ID e59267, 2013
33. E. A. Dennis, J. Cao, Y.-H. Hsu, V. Magrioti, and G. Kokotos, "PhospholipaseA2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention," Chemical Reviews, vol. 111, no. 10, pp. 6130-6185, 2011
34. S. Bione, P. D'Adamo, E. Maestrini, A. K. Gedeon, P. A. Bolhuis, and D. Toniolo, "A novelX-linked gene, G4. 5. is responsible for Barth syndrome," Nature Genetics, vol. 12, no. 4, pp. 385-389, 1996
35. Z. Gu, F. Valianpour, S. Chen et al., "Aberrant cardiolipin metabolism in the yeast taz1 mutant: A model for Barth syndrome," Molecular Microbiology, vol. 51, no. 1, pp. 149-158, 2004
36. F. M. Vaz, R. H. Houtkooper, F. Valianpour, P. G. Barth, and R. J. A. Wanders, "Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism," Journal of Biological Chemistry, vol. 278, no. 44, pp. 43089-43094, 2003
37. J. Cao, Y. Liu, J. Lockwood, P. Burn, and Y. Shi, "A novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA:lysocardiolipin acyltransferase (ALCAT1) in mouse,"The Journal of Biological Chemistry, vol. 279, no. 30, pp. 31727-31734, 2004
38. W. A. Taylor and G. M. Hatch, "Identification of the human mitochondrial linoleoyl-coenzyme a monolysocardiolipin acyltransferase (MLCL AT-1),"The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30360-30371, 2009
39. Y. Xu, R. I. Kelley, T. J. J. Blanck, andM. Schlame, "Remodeling of cardiolipin by phospholipid transacylation," Journal of Biological Chemistry, vol. 278, no. 51, pp. 51380-51385, 2003
40. A. Yamashita, T. Sugiura, and K. Waku, "Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids andmetabolism of bioactive lipids in mammalian cells," Journal of Biochemistry, vol. 122, no. 1, pp. 1-16, 1997
41. P. G. Barth, H. R. Scholte, J. A. Berden et al., "An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes," Journal of the Neurological Sciences, vol. 62, no. 1-3, pp. 327-355, 1983
42. P. G. Barth, R. J. A. Wanders, and P. Vreken, "X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)- MIM 302060," Journal of Pediatrics, vol. 135, no. 3, pp. 273-276, 1999
43. F. Valianpour, R. J. A. Wanders, H. Overmars et al., "Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): A study in cultured skin fibroblasts," The Journal of Pediatrics, vol. 141, no. 5, pp. 729-733, 2002
44. M. Schlame, J. A. Towbin, P. M. Heerdt, R. Jehle, S. DiMauro, and T. J. J. Blanck, "Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome," Annals of Neurology, vol. 51, no. 5, pp. 634-637, 2002
45. M. Schlame, R. I. Kelley, A. Feigenbaum et al., "Phospholipid abnormalities in children with Barth syndrome," Journal of the American College of Cardiology, vol. 42, no. 11, pp. 1994-1999, 2003
46. R. Chen, T. Tsuji, F. Ichida et al., "Mutation analysis of the G4. 5 gene in patients with isolated left ventricular noncompaction," Molecular Genetics and Metabolism, vol. 77, no. 4, pp. 319-325, 2002
47. P. D'Adamo, L. Fassone, A. Gedeon et al., "The X-linked gene G4. 5 is responsible for different infantile dilated cardiomyopathies," American Journal of Human Genetics, vol. 61, no. 4, pp. 862-867, 1997
48. A. Hijikata, K. Yura, O. Ohara, and M. Go, "Structural and functional analyses of Barth syndrome-causing mutations and alternative splicing in the tafazzin acyltransferase domain," Meta Gene, vol. 4, pp. 92-106, 2015
49. A. Bowron, J. Honeychurch, M. Williams et al., "Barth syndrome without tetralinoleoyl cardiolipin deficiency: A possible ameliorated phenotype," Journal of InheritedMetabolic Disease, vol. 38, no. 2, pp. 279-286, 2015
50. S. M. Claypool, K. Whited, S. Srijumnong, X. Han, and C. M. Koehler, "Barth syndrome mutations that cause tafazzin complex lability," Journal of Cell Biology, vol. 192, no. 3, pp. 447-462, 2011
51. R. H. Houtkooper and F. M. Vaz, "Cardiolipin, the heart of mitochondrial metabolism," Cellular and Molecular Life Sciences, vol. 65, no. 16, pp. 2493-2506, 2008
52. H. Cheng, D. J. Mancuso, X. Jiang et al., "Shotgun lipidomics reveals the temporally dependent, highly diversified cardiolipin profile in the mammalian brain: Temporally coordinated postnatal diversification of cardiolipin molecular species with neuronal remodeling," Biochemistry, vol. 47, no. 21, pp. 5869-5880, 2008
53. M. G. Baile, M. Sathappa, Y.-W. Lu et al., "Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast," The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1768-1778, 2014
54. C. Ye, W. Lou, Y. Li et al., "Deletion of the Cardiolipin-specific Phospholipase Cld1 rescues growth and life span defects in the TafazzinMutant: implications for Barth Syndrome," The Journal of Biological Chemistry, vol. 289, no. 6, pp. 3114-3125, 2014
55. D. G. Gardner and D. Shoback, Greenspan's Basic and Clinical Endocrinology, chapter 17, McGraw-Hill, New York, NY, USA, 9th edition, 2011
56. D. M. Nathan, "Long-term complications of diabetes mellitus," The New England Journal ofMedicine, vol. 328, no. 23, pp. 1676-1685, 1993
57. X. Han, D. R. Abendschein, J. G. Kelley, and R. W. Gross, "Diabetes-induced changes in specific lipid molecular species in rat myocardium," Biochemical Journal, vol. 352, no. 1, pp. 79-89, 2000
58. X. Han, J. Yang, H. Cheng, K. Yang,D. R. Abendschein, and R. W. Gross, "Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction," Biochemistry, vol. 44, no. 50, pp. 16684-16694, 2005
59. X. Han, J. Yang, K. Yang, Z. Zhongdan, D. R. Abendschein, and R. W. Gross, "Alterations inmyocardial cardiolipin content and composition occur at the very earliest stages of diabetes: A shotgun lipidomics study," Biochemistry, vol. 46, no. 21, pp. 6417-6428, 2007
60. H.-J. Pan, Y. Lin, Y. E. Chen, D. E. Vance, and E. H. Leiter, "Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism," Vascular Pharmacology, vol. 45, no. 1, pp. 65-71, 2006
61. K. Pfeiffer, V. Gohil, R. A. Stuart et al., "Cardiolipin stabilizes respiratory chain supercomplexes," The Journal of Biological Chemistry, vol. 278, no. 52, pp. 52873-52880, 2003
62. E. Mileykovskaya andW. Dowhan, "Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes," Chemistry and Physics of Lipids, vol. 179, pp. 42-48, 2014
63. V. Koshkin and M. L. Greenberg, "Cardiolipin prevents ratedependent uncoupling and provides osmotic stability in yeast mitochondria," Biochemical Journal, vol. 364, no. 1, pp. 317-322, 2002
64. M. N. Sack, "Type 2 diabetes, mitochondrial biology and the heart," Journal ofMolecular and Cellular Cardiology, vol. 46, no. 6, pp. 842-849, 2009
65. D. L. Carden and D. N. Granger, "Pathophysiology of ischaemia-reperfusion injury,"TheJournal of Pathology, vol. 190, no. 3, pp. 255-266, 2000
66. C. E. Ganote, "Contraction band necrosis and irreversible myocardial injury," Journal of Molecular and Cellular Cardiology, vol. 15, no. 2, pp. 67-73, 1983
67. M. Ruiz-Meana, D. Garcia-Dorado, B. Hofstaetter, H. M. Piper, and J. Soler-Soler, "Propagation of cardiomyocyte hypercontracture by passage of Na+ through gap junctions," Circulation Research, vol. 85, no. 3, pp. 280-287, 1999
68. D. G. Allen and C. H. Orchard, "Myocardial contractile function during ischemia and hypoxia," Circulation Research, vol. 60, no. 2, pp. 153-168, 1987
69. Y. Chandrashekhar, A. J. Prahash, S. Sen, S. Gupta, and I. S. Anand, "Cardiomyocytes from hearts with left ventricular dysfunction after ischemia-reperfusion do notmanifest contractile abnormalities," Journal of the American College of Cardiology, vol. 34, no. 2, pp. 594-602, 1999
70. A. L. Wit and M. J. Janse, "Reperfusion arrhythmias and sudden cardiac death: A century of progress toward an understanding of themechanisms," Circulation Research, vol. 89, no. 9, pp. 741-743, 2001
71. W. E. Cascio, H. Yang, B. J. Muller-Borer, and T. A. Johnson, "Ischemia-induced arrhythmia: The role of connexins, gap junctions, and attendant changes in impulse propagation," Journal of Electrocardiology, vol. 38, no. 4, supplement, pp. 55-59, 2005
72. A. V. Ghuran and A. J. Camm, "Ischaemic heart disease presenting as arrhythmias," British Medical Bulletin, vol. 59, no. 1, pp. 193-210, 2001
73. N. Luqman, R. J. Sung, C.-L. Wang, and C.-T. Kuo, "Myocardial ischemia and ventricular fibrillation: pathophysiology and clinical implications," International Journal of Cardiology, vol. 119, no. 3, pp. 283-290, 2007
74. I. V. Kazbanov, R. H. Clayton, M. P. Nash et al., "Effect of global cardiac ischemia on human ventricular fibrillation: insights from a multi-scale mechanistic model of the human heart," PLoS Computational Biology, vol. 10, no. 11, Article ID e1003891, 2014
75. R. Ferrari, C. Ceconi, S. Curello et al., "Role of oxygen free radicals in ischemic and reperfused myocardium," The American Journal of Clinical Nutrition, vol. 53, no. 1, pp. 215S-222S, 1991
76. R. A. Kloner, K. Przyklenk, and P. Whittaker, "Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues," Circulation, vol. 80, no. 5, pp. 1115-1127, 1989
77. T. Kalogeris, Y. Bao, and R. J. Korthuis, "Mitochondrial reactive oxygen species: A double edged sword in ischemia/reperfusion vs preconditioning," Redox Biology, vol. 2, no. 1, pp. 702-714, 2014
78. G. Paradies, G. Petrosillo, M. Pistolese,N. Di Venosa,D. Serena, and F. M. Ruggiero, "Lipid peroxidation and alterations to oxidative metabolism in mitochondria isolated from rat heart subjected to ischemia and reperfusion," Free Radical Biology and Medicine, vol. 27, no. 1-2, pp. 42-50, 1999
79. E. J. Lesnefsky, T. J. Slabe, M. S. K. Stoll, P. E. Minkler, and C. L. Hoppel, "Myocardial ischemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 280, no. 6, pp. H2770-H2778, 2001
80. G. Paradies, G. Petrosillo, M. Pistolese, N. Di Venosa, A. Federici, and F. M. Ruggiero, "Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin," Circulation Research, vol. 94, no. 1, pp. 53-59, 2004
81. G. Petrosillo, F. M. Ruggiero, N. Di Venosa, and G. Paradies, "Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin," The FASEB Journal, vol. 17, no. 6, pp. 714-716, 2003
82. V. E. Kagan, V. A. Tyurin, J. Jiang et al., "Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors," Nature Chemical Biology, vol. 1, no. 4, pp. 223-232, 2005
83. Y. A. Vladimirov, E. V. Proskurnina, D. Y. Izmailov et al., "Cardiolipin activates cytochrome c peroxidase activity since it facilitates H2O2 access to heme," Biochemistry, vol. 71, no. 9, pp. 998-1005, 2006
84. K. Nomura, H. Imai, T. Koumura, T. Kobayashi, and Y. Nakagawa, "Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis," Biochemical Journal, vol. 351, no. 1, pp. 183-193, 2000
85. M. Lutter, G. A. Perkins, and X. Wang, "The pro-apoptotic Bcl-2 family member tBid localizes to mitochondrial contact sites," BMC Cell Biology, vol. 2, article 22, 2001
86. S. Lucken-Ardjomande, S. Montessuit, and J.-C. Martinou, "Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane," Cell Death and Differentiation, vol. 15, no. 5, pp. 929-937, 2008
87. M.-A. Sani, E. J. Dufourc, and G. Gröbner, "How does the Bax-1 targeting sequence interact with mitochondrialmembranes? The role of cardiolipin," Biochimica et Biophysica Acta: Biomembranes, vol. 1788, no. 3, pp. 623-631, 2009
88. R. F. Epand, J.-C. Martinou, M. Fornallaz-Mulhauser, D. W. Hughes, and R. M. Epand, "The apoptotic protein tBid promotes leakage by alteringmembrane curvature," The Journal of Biological Chemistry, vol. 277, no. 36, pp. 32632-32639, 2002
89. R. Ross, "The pathogenesis of atherosclerosis: A perspective for the 1990s," Nature, vol. 362, no. 6423, pp. 801-809, 1993
90. A. Tuominen, Y. I. Miller, L. F. Hansen, Y. A. Kesäniemi, J. L. Witztum, and S. Hörkkö, "A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 9, pp. 2096-2102, 2006
91. H. Zhong, J. Lu, L. Xia, M. Zhu, andH. Yin, "Formation of electrophilic oxidation products from mitochondrial cardiolipin in vitro and in vivo in the context of apoptosis and atherosclerosis," Redox Biology, vol. 2, pp. 878-883, 2014
92. I. Marai, M. Shechter, P. Langevitz et al., "Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease,"The American Journal of Cardiology, vol. 101, no. 8, pp. 1094-1097, 2008
93. O. Türkoglu, N. Baris, N. Kütükcüler, O. Senarslan, S. Güneri, and G. Atilla, "Evaluation of serum anti-cardiolipin and oxidized low-density lipoprotein levels in chronic periodontitis patients with essential hypertension," Journal of Periodontology, vol. 79, no. 2, pp. 332-340, 2008
94. D. Lopez, K. Kobayashi, J. T. Merrill, E. Matsuura, and L. R. Lopez, "IgG autoantibodies against 2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome," Clinical and Developmental Immunology, vol. 10, no. 2-4, pp. 203-211, 2003
95. J. Su, A. G. Frostegard, X. Hua et al., "Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus," Journal of Rheumatology, vol. 40, no. 11, pp. 1856-1864, 2013
96. V. N. Bochkov, O. V. Oskolkova, K. G. Birukov, A.-L. Levonen, C. J. Binder, and J. Stöckl, "Generation and biological activities of oxidized phospholipids," Antioxidants & Redox Signaling, vol. 12, no. 8, pp. 1009-1059, 2010
97. A. G. Frostegard, J. Su, X. Hua, M. Vikström, U. De Faire, and J. Frostegard, "Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development," PLoS ONE, vol. 9, no. 12, Article ID e111764, 2014
98. J. Su, X. Hua, M. Vikström et al., "Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: A prospective study," BMC Cardiovascular Disorders, vol. 13, article 1, 2013
99. M. Wan, X. Hua, J. Su et al., "Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5," Atherosclerosis, vol. 235, no. 2, pp. 592-598, 2014
100. K. M. Davey, J. S. Parboosingh, D. R. McLeod et al., "Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition," Journal of Medical Genetics, vol. 43, no. 5, pp. 385-393, 2006
101. P. D. D'Silva, B. Schilke,W. Walter, A. Andrew, and E. A. Craig, "J protein cochaperone of the mitochondrial inner membrane required for protein import into the mitochondrial matrix," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 13839-13844, 2003
102. D. Mokranjac,M. Sichting, W. Neupert, and K. Hell, "Tim14, a novel key component of the import motor of the TIM23 protein translocase ofmitochondria," The EMBO Journal, vol. 22, no. 19, pp. 4945-4956, 2003
103. P. Rehling, N. Pfanner, and C. Meisinger, "Insertion of hydrophobic membrane proteins into the inner mitochondrial membrane-a guided tour," Journal of Molecular Biology, vol. 326, no. 3, pp. 639-657, 2003
104. N. Gebert, A. S. Joshi, S. Kutik et al., "Mitochondrial cardiolipin involved in outer membrane protein biogenesis: implications for Barth syndrome," Current Biology, vol. 19, no. 24, pp. 2133-2139, 2009
105. T. Endo, M. Eilers, and G. Schatz, "Binding of a tightly folded artificial mitochondrial precursor protein to the mitochondrial outer membrane involves a lipid-mediated conformational change," The Journal of Biological Chemistry, vol. 264, no. 5, pp. 2951-2956, 1989
106. T. Endo and G. Schatz, "Latent membrane perturbation activity of a mitochondrial precursor protein is exposed by unfolding," The EMBO Journal, vol. 7, no. 4, pp. 1153-1158, 1988
107. M. Eilers, T. Endo, and G. Schatz, "Adriamycin, a drug interacting with acidic phospholipids, blocks import of precursor proteins by isolated yeast mitochondria," The Journal of Biological Chemistry, vol. 264, no. 5, pp. 2945-2950, 1989
108. F. Jiang, M. T. Ryan,M. Schlame et al., "Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function," The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22387-22394, 2000
109. R. Richter-Dennerlein, A. Korwitz, M. Haag et al., "DNAJC19, a mitochondrial cochaperone associated with cardiomyopathy, forms a complexwith prohibitins to regulate cardiolipin remodeling," Cell Metabolism, vol. 20, no. 1, pp. 158-171, 2014
110. J. J. V. McMurray and M. A. Pfeffer, "Heart failure," The Lancet, vol. 365, no. 9474, pp. 1877-1889, 2005
111. H. K. Saini-Chohan, M. G. Holmes, A. J. Chicco et al., "Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure," Journal of Lipid Research, vol. 50, no. 8, pp. 1600-1608, 2009
112. G. C. Sparagna, A. J. Chicco, R. C. Murphy et al., "Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure," Journal of Lipid Research, vol. 48, no. 7, pp. 1559-1570, 2007
113. K. C. Chatfield, G. C. Sparagna, C. C. Sucharov et al., "Dysregulation of cardiolipin biosynthesis in pediatric heart failure," Journal of Molecular and Cellular Cardiology, vol. 74, pp. 251-259, 2014
114. C. H. Le, C. M. Mulligan, M. A. Routh et al., "Delta-6-desaturase links polyunsaturated fatty acid metabolism with phospholipid remodeling and disease progression in heart failure," Circulation:Heart Failure, vol. 7, no. 1, pp. 172-183, 2014
115. D. K. Reibel, B. O'Rourke, K. A. Foster, H. Hutchinson, C. E. Uboh, and R. L. Kent, "Altered phospholipid metabolism in pressure-overload hypertrophied hearts," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 250, no. 1, pp. H1-H6, 1986
116. M. Rosca, P. Minkler, and C. L. Hoppel, "Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV," Biochimica et Biophysica Acta: Bioenergetics, vol. 1807, no. 11, pp. 1373-1382, 2011
117. D. S. Fredrickson, "The inheritance of high density lipoprotein deficiency (Tangier disease)," The Journal of Clinical Investigation, vol. 43, pp. 228-236, 1964
118. J. F. Oram, "Tangier disease and ABCA1," Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1529, no. 1-3, pp. 321-330, 2000
119. S. Rust, M. Rosier, H. Funke et al., "Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1," Nature Genetics, vol. 22, no. 4, pp. 352-355, 1999
120. B. L. Knight, "ATP-binding cassette transporter A1: regulation of cholesterol efflux," Biochemical Society Transactions, vol. 32, no. 1, pp. 124-127, 2004
121. N. Wang, D. L. Silver, C. Thiele, and A. R. Tall, "ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein," The Journal of Biological Chemistry, vol. 276, no. 26, pp. 23742-23747, 2001
122. M. Fobker, R. Voss, H. Reinecke, C. Crone, G. Assmann, and M. Walter, "Accumulation of cardiolipin and lysocardiolipin in fibroblasts fromTangier disease subjects," FEBS Letters, vol. 500, no. 3, pp. 157-162, 2001
123. C. Maack and B. O'Rourke, "Excitation-contraction coupling and mitochondrial energetics," Basic Research in Cardiology, vol. 102, no. 5, pp. 369-392, 2007
124. M.-S. Beaudoin, C. G. R. Perry, A. M. Arkell et al., "Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats," The Journal of Physiology, vol. 592, no. 12, pp. 2519-2533, 2014
125. D. Montaigne, X. Marechal, A. Coisne et al., "Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients," Circulation, vol. 130, no. 7, pp. 554-564, 2014
126. N. S. Dhalla, S. Rangi, S. Zieroth, and Y.-J. Xu, "Alterations in sarcoplasmic reticulum and mitochondrial functions in diabetic cardiomyopathy," Experimental & Clinical Cardiology, vol. 17, no. 3, pp. 115-120, 2012
127. M. Zhang, J. Wei, H. Shan et al., "Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy," PLoS ONE, vol. 8, no. 6, Article ID e66779, 2013
128. X. Wang, M. Bathina, J. Lynch et al., "Deletion ofMCL-1 causes lethal cardiac failure and mitochondrial dysfunction," Genes & Development, vol. 27, no. 12, pp. 1351-1364, 2013
129. D. Hayashi, S. Ohshima, S. Isobe et al., "Increased 99mTcsestamibi washout reflects impaired myocardial contractile and relaxation reserve during dobutamine stress due to mitochondrial dysfunction in dilated cardiomyopathy patients," Journal of the American College of Cardiology, vol. 61, no. 19, pp. 2007-2017, 2013
130. C. Jung, A. S. Martins, E. Niggli, andN. Shirokova, "Dystrophic cardiomyopathy: Amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways," Cardiovascular Research, vol. 77, no. 4, pp. 766-773, 2008
131. Y. Burelle, M. Khairallah, A. Ascah et al., "Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart," Journal of Molecular and Cellular Cardiology, vol. 48, no. 2, pp. 310-321, 2010
132. E. T. Chouchani, C. Methner, G. Buonincontri et al., "Complex I deficiency due to selective loss of Ndufs4 in the mouse heart results in severe hypertrophic cardiomyopathy," PLoS ONE, vol. 9, no. 4, Article ID e94157, 2014
133. C. M. Hagen, F. H. Aidt, P. L. Hedley et al., "Mitochondrial haplogroups modify the risk of developing hypertrophic cardiomyopathy in a Danish population," PLoS ONE, vol. 8, no. 8, Article ID e71904, 2013
134. X. Liu, B. Ye, S. Miller et al., "Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy," Molecular and Cellular Biology, vol. 32, no. 21, pp. 4493-4504, 2012
135. L. Lin, V. K. Sharma, and S.-S. Sheu, "Mechanisms of reduced mitochondrial Ca2+ accumulation in failing hamster heart," Pflügers Archi-European Journal of Physiology, vol. 454, no. 3, pp. 395-402, 2007
136. G. Karamanlidis, C. F. Lee, L. Garcia-Menendez et al., "Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure," CellMetabolism, vol. 18, no. 2, pp. 239-250, 2013
137. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy revisited," Circulation, vol. 115, no. 25, pp. 3213-3223, 2007
138. M. Fry and D. E. Green, "Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain,"The Journal of Biological Chemistry, vol. 256, no. 4, pp. 1874-1880, 1981
139. M. Zhang, E. Mileykovskaya, and W. Dowhan, "Gluing the respiratory chain together: cardiolipin is required for supercomplex formation in the inner mitochondrialmembrane," The Journal of Biological Chemistry, vol. 277, no. 46, pp. 43553-43556, 2002
140. M. Zhang, E. Mileykovskaya, and W. Dowhan, "Cardiolipin is essential for organization of complexes III and IV into a supercomplex in intact yeast mitochondria," The Journal of Biological Chemistry, vol. 280, no. 33, pp. 29403-29408, 2005
141. V. M. Gohil, P. Hayes, S. Matsuyama, H. Schägger, M. Schlame, and M. L. Greenberg, "Cardiolipin biosynthesis and mitochondrial respiratory chain function are interdependent," The Journal of Biological Chemistry, vol. 279, no. 41, pp. 42612-42618, 2004
142. A. Ranieri, D. Millo, G. Di Rocco et al., "Immobilized cytochrome c bound to cardiolipin exhibits peculiar oxidation state-dependent axial heme ligation and catalytically reduces dioxygen," Journal of Biological Inorganic Chemistry, vol. 20, no. 3, pp. 531-540, 2015
143. K. Beyer and M. Klingenberg, "ADP/ATP carrier protein from beef heart mitochondria has high amounts of tightly bound cardiolipin, as revealed by 31P nuclear magnetic resonance," Biochemistry, vol. 24, no. 15, pp. 3821-3826, 1985
144. G. Paradies and F. M. Ruggiero, "The effect of doxorubicin on the transport of pyruvate in rat-heart mitochondria," Biochemical and Biophysical Research Communications, vol. 156, no. 3, pp. 1302-1307, 1988
145. B. Kadenbach, P. Mende, H. V. J. Kolbe, I. Stipani, and F. Palmieri, "Themitochondrial phosphate carrier has an essential requirement for cardiolipin," FEBS Letters, vol. 139, no. 1, pp. 109-112, 1982
146. G. Paradies, G. Petrosillo, M. Pistolese, and F. M. Ruggiero, "The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles," FEBS Letters, vol. 466, no. 2-3, pp. 323-326, 2000
147. A. Musatov, "Contribution of peroxidized cardiolipin to inactivation of bovine heart cytochrome c oxidase," Free Radical Biology and Medicine, vol. 41, no. 2, pp. 238-246, 2006
148. H. Schägger and K. Pfeiffer, "Supercomplexes in the respiratory chains of yeast and mammalian mitochondria," The EMBO Journal, vol. 19, no. 8, pp. 1777-1783, 2000
149. M. McKenzie, M. Lazarou, D. R. Thorburn, and M. T. Ryan, "Mitochondrial respiratory chain supercomplexes are destabilized in barth syndrome patients," Journal of Molecular Biology, vol. 361, no. 3, pp. 462-469, 2006
150. T. A. Ajith and T. G. Jayakumar, "Mitochondria-targeted agents: future perspectives of mitochondrial pharmaceutics in cardiovascular diseases," World Journal of Cardiology, vol. 6, no. 10, pp. 1091-1099, 2014
151. K. Zhao, G.-M. Zhao, D. Wu et al., "Cell-permeable peptide antioxidants targeted to inner mitochondrialmembrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury," Journal of Biological Chemistry, vol. 279, no. 33, pp. 34682-34690, 2004
152. J. Cho, K. Won, D. Wu et al., "Potent mitochondria-targeted peptides reduce myocardial infarction in rats," Coronary Artery Disease, vol. 18, no. 3, pp. 215-220, 2007
153. H. H. Szeto, "Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury," Antioxidants & Redox Signaling, vol. 10, no. 3, pp. 601-619, 2008
154. G. F. Kelso, A. Maroz, H. M. Cochemé et al., "A mitochondriatargeted macrocyclic Mn(II) superoxide dismutase mimetic," Chemistry & Biology, vol. 19, no. 10, pp. 1237-1246, 2012
155. R. A. J. Smith, C. M. Porteous, C. V. Coulter, and M. P. Murphy, "Selective targeting of an antioxidant to mitochondria," European Journal of Biochemistry, vol. 263, no. 3, pp. 709-716, 1999
156. G. F. Kelso, C. M. Porteous, C. V. Coulter et al., "Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties," The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4588-4596, 2001
157. S. E. Brown, M. F. Ross, A. Sanjuan-Pla, A.-R. B. Manas, R. A. J. Smith, and M. P. Murphy, "Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium-conjugated -lipoyl derivative," Free Radical Biology and Medicine, vol. 42, no. 12, pp. 1766-1780, 2007
158. A. Sickmann, J. Reinders, Y. Wagner et al., "The proteome of Saccharomyces cerevisiae mitochondria," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13207-13212, 2003
159. U. Nair and D. J. Klionsky, "Molecular mechanisms and regulation of specific and nonspecific autophagy pathways in yeast," The Journal of Biological Chemistry, vol. 280, no. 51, pp. 41785-41788, 2005
160. K. Okamoto, "Organellophagy: eliminating cellular building blocks via selective autophagy," The Journal of Cell Biology, vol. 205, no. 4, pp. 435-445, 2014
161. K. Wang and D. J. Klionsky, "Mitochondria removal by autophagy," Autophagy, vol. 7, no. 3, pp. 297-300, 2011
162. A. G. Moyzis, J. Sadoshima, and A. B. Gustafsson, "Mending a broken heart: The role of mitophagy in cardioprotection," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 3, pp. H183-H192, 2015
163. A. Nakai,O. Yamaguchi, T. Takeda et al., "Therole of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress," Nature Medicine, vol. 13, no. 5, pp. 619-624, 2007
164. P.-J. Linton, M. Gurney, D. Sengstock, R. M. Mentzer Jr., and R. A. Gottlieb, "This old heart: cardiac aging and autophagy," Journal ofMolecular and Cellular Cardiology, vol. 83, pp. 44-54, 2015
165. H. D. Sybers, J. Ingwall, and M. DeLuca, "Autophagy in cardiac myocytes," Recent Advances in Studies on Cardiac Structure and Metabolism, vol. 26-29, no. 12, pp. 453-463, 1976
166. L. Yan, D. E. Vatner, S.-J. Kim et al., "Autophagy in chronically ischemic myocardium," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13807-13812, 2005
167. A. Hamacher-Brady, N. R. Brady, S. E. Logue et al., "Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy," Cell Death and Differentiation, vol. 14,no. 1, pp. 146-157, 2007
168. C. Huang, S. Yitzhaki, C. N. Perry et al., "Autophagy induced by ischemic preconditioning is essential for cardioprotection," Journal of Cardiovascular Translational Research, vol. 3, no. 4, pp. 365-373, 2010
169. L. Valentim, K. M. Laurence, P. A. Townsend et al., "Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury," Journal of Molecular and Cellular Cardiology, vol. 40, no. 6, pp. 846-852, 2006
170. Y. Matsui, H. Takagi, X. Qu et al., "Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMPactivated protein kinase and beclin 1 in mediating autophagy," Circulation Research, vol. 100, no. 6, pp. 914-922, 2007
171. L.-T. Wang, B.-L. Chen, C.-T. Wu, K.-H. Huang, C.-K. Chiang, and S. H. Liu, "Protective role of AMP-activated protein kinase-evoked autophagy on an in vitro model of ischemia/reperfusion-induced renal tubular cell injury," PLoS ONE, vol. 8, no. 11,Article ID e79814, 2013
172. R. Guo and J. Ren, "Deficiency in AMPK attenuates ethanolinduced cardiac contractile dysfunction through inhibition of autophagosome formation," Cardiovascular Research, vol. 94, no. 3, pp. 480-491, 2012
173. M. A. Paiva, Z. Rutter-Locher, L. M. Goncalves et al., "Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 300, no. 6, pp. H2123-H2134, 2011
174. C. Huang, W. Liu, C. N. Perry et al., "Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 2, pp. H570-H579, 2010
175. R. S. Decker and K. Wildenthal, "Lysosomal alterations in hypoxic and reoxygenated hearts. I. Ultrastructural and cytochemical changes," The American Journal of Pathology, vol. 98, no. 2, pp. 425-444, 1980
176. X. Ma, H. Liu, S. R. Foyil et al., "Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury," Circulation, vol. 125, no. 25, pp. 3170-3181, 2012
177. C. T. Chu, J. Ji,R. K. Dagda et al., "Cardiolipin externalizationto the outer mitochondrialmembrane acts as an elimination signal formitophagy in neuronal cells," Nature Cell Biology, vol. 15, no. 10, pp. 1197-1205, 2013
178. C. T. Chu, H. Bayir, and V. E. Kagan, "LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons: implications for Parkinson disease," Autophagy, vol. 10, no. 2, pp. 376-378, 2014
179. L. Wang, X. Liu, J. Nie et al., "ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis," Hepatology, vol. 61, no. 2, pp. 486-496, 2015
180. W. Huang, W. Choi, W. Hu et al., "Crystal structure and biochemical analyses reveal Beclin 1 as a novel membrane binding protein," Cell Research, vol. 22, no. 3, pp. 473-489, 2012
181. H. Mellor and P. J. Parker, "The extended protein kinase C superfamily," Biochemical Journal, vol. 332, part 2, pp. 281-292, 1998
182. S. P. Marso and D. M. Stern, Diabetes and Cardiovascular Disease: Integrating Science and Clinical Medicine, Lippincott Williams &Wilkins, 2003
183. D. R. Meldrum, J. C. Cleveland Jr., X. Meng et al., "Protein kinase C isoform diversity in preconditioning," Journal of Surgical Research, vol. 69, no. 1, pp. 183-187, 1997
184. M. Munakata, C. Stamm, I. Friehs et al., "Protective effects of protein kinase C duringmyocardial ischemia require activation of phosphatidyl-inositol specific phospholipase C," Annals of Thoracic Surgery, vol. 73, no. 4, pp. 1236-1245, 2002
185. W. Jiang, L. Bian, L.-J. Ma, R.-Z. Tang, S. Xun, and Y.-W. He, "Hyperthermia-induced apoptosis in Tca8113 cells is inhibited by heat shock protein 27 through blocking phospholipid scramblase 3 phosphorylation," International Journal of Hyperthermia, vol. 26, no. 6, pp. 523-537, 2010
186. Y. He, J. Liu,D. Grossman et al., "Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C- induces its activation and facilitates mitochondrial targeting of tBid," Journal of Cellular Biochemistry, vol. 101, no. 5, pp. 1210-1221, 2007
187. J. E. Kowalczyk, M. Beresewicz, B. Gajkowska, and B. Zabocka, "Association of protein kinase C delta and phospholipid scramblase 3 in hippocampal mitochondria correlates with neuronal vulnerability to brain ischemia," Neurochemistry International, vol. 55, no. 1-3, pp. 157-163, 2009
188. Q. Zhong, G. Li, J. Gvozdenovic-Jeremic, and M. L. Greenberg, "Up-regulation of the cell integrity pathway in Saccharomyces cerevisiae suppresses temperature sensitivity of the pgs1? mutant," Journal of Biological Chemistry, vol. 282, no. 22, pp. 15946-15953, 2007
189. S. Nomoto, Y. Watanabe, J. Ninomiya-Tsuji et al., "Functional analyses of mammalian protein kinase C isozymes in budding yeast and mammalian fibroblasts," Genes to Cells, vol. 2, no. 10, pp. 601-614, 1997
190. W. Korytowski, L. V. Basova, A. Pilat, R. M. Kernstock, and A. W. Girotti, "Permeabilization of the mitochondrial outer membrane by bax/truncated Bid (tBid) proteins as sensitized by cardiolipin hydroperoxide translocation: mechanistic implications for the intrinsic pathway of oxidative apoptosis," The Journal of Biological Chemistry, vol. 286, no. 30, pp. 26334-26343, 2011.